At-home compounding preparation of slow desensitization of elexacaftor/tezacaftor/ivacaftor for delayed hypersensitivity rash.
Pediatr Pulmonol
; 57(7): 1779-1781, 2022 07.
Article
em En
| MEDLINE
| ID: mdl-35451238
ABSTRACT
As elexacaftor/tezacaftor/ivacaftor has proven to have robust clinical efficacy for eligible persons with cystic fibrosis, desensitization should be offered to those with maculopapular eruption hypersensitivity reactions to achieve tolerance. As presented in this case, if provided with tools for crushing and mixing the medication, a successful escalation protocol can be completed at home without coordinating the help of a compound pharmacy.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Fibrose Cística
/
Exantema
/
Agonistas dos Canais de Cloreto
/
Hipersensibilidade Tardia
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article